NCT06309290Recruiting
Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy
Prehabilitation Based on Resistance-exercise Training in Women With Breast Cancer Undergoing Neoadjuvant Therapy: From Molecular Mechanism to Clinical Benefits
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
Breast cancer stands as the foremost cause of cancer-related deaths among women worldwide, with the highest incidence of any cancer type. The choice of therapeutic interventions hinges upon factors like cancer stage, cell subtype, and tumor size. Consequently, individuals with more aggressive tumors, such as HER+2 and Triple Negative, or larger tumors often undergo neoadjuvant chemotherapy before breast surgery. However, these anticancer treatments come with side effects like cancer-related fatigue, reduced functional capacity, and changes in body composition, notably skeletal muscle atrophy. Skeletal muscle loss correlates with heightened mortality rates, cardiotoxicity, and diminished quality of life, underscoring the need for early therapeutic interventions. One such promising strategy is prehabilitation, which involves resistance-exercise training aimed at bolstering skeletal muscle mass from the outset of the disease, even preceding breast surgery. Resistance-exercise training has shown favorable effects on women undergoing adjuvant therapy or survivors of breast cancer, however, its molecular and clinical effects in women with breast cancer undergoing neoadjuvant therapy are unknown.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- First submitted
- 29 Feb 2024
- Start date
- 1 Jan 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Universidad de La Frontera
- Diseases
- Childhood cancers
- NCT number
- NCT06309290
What you commit to
- Study type: Interventional
- Planned participants: 68
- From 1 Jan 2025 to the primary completion date, 31 Aug 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous antineoplastic treatment
Other illness
- Present comorbidities that interact with the metabolism and mobility of the muscles of the body and that do not allow the (safe) performance of strength exercises (e.g., debilitating arthritis, all neurological disorders, paralysis, among others).
Lab values
- Severe or uncontrolled cardiovascular disease, cardiac ejection fraction less than 50%
Other
- Use of nutritional supplements (leucine, glutamine, casein, whey protein, fatty acids and creatine).
Who the study is looking for
- Postmenopausal women with breast cancer in stages I, II and III with luminal breast tumor, HER2+ or TNBC
- Indication for neoadjuvant chemotherapy
- Candidates for curative breast surgery
- Body mass index: 18.5 \<BMI \<30 kg/m2
- Sedentary (does not perform scheduled or planned physical activity ≥ 2 times a week)
- Willingness to participate in the study and follow the proposed prehabilitation scheme.
Sex: Female · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fundacion Arturo Lopez Perez Coordinator of this site? Confirm its status | Santiago | Chile | Recruiting |
| Department of Rehabilitation Sciences, Faculty of Medicine, Universidad de La Frontera. Temuco, Chile Coordinator of this site? Confirm its status | Temuco | Chile | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.